Summary
Boston Scientific Corporation (BSX) announced on January 15, 2009, a significant adverse development concerning its intellectual property related to drug-eluting stents. The U.S. Court of Appeals for the Federal Circuit ruled that a key patent, which partially covers drug-eluting stent technology and coating systems, is invalid due to obviousness over prior art. This decision overturns a 2005 jury verdict that had previously found the patent valid and infringed by Johnson & Johnson's Cypher® stent system. This ruling represents a material challenge to Boston Scientific's patent portfolio and could impact its competitive position in the lucrative drug-eluting stent market. Investors should closely monitor the company's response and any potential strategic implications. Boston Scientific is currently evaluating its options for challenging this appellate court decision, and further developments in this litigation will be crucial for understanding the long-term financial and market consequences for the company.
Key Highlights
- 1Boston Scientific's patent covering drug-eluting stents and coating systems has been declared invalid by the U.S. Court of Appeals for the Federal Circuit.
- 2The appellate court found the patent invalid due to obviousness over prior art, overturning a previous jury verdict.
- 3The patent was previously upheld as valid and infringed by Johnson & Johnson's Cypher® Sirolimus-Eluting Stent System.
- 4The company is currently considering its options to challenge this appellate court decision.
- 5This ruling pertains to a significant area of Boston Scientific's product line, potentially impacting its market position and future revenue streams.
- 6A press release dated January 15, 2009, detailing this event has been filed as an exhibit.